Protection by glia-conditioned medium in a cell model of Huntington disease

PLoS Currents

Volumn , Issue , 2012, Pages

  Ruiz, Carolina ^a   Casarejos, Maria Jose ^a   Gomez, Ana ^a   Solano, Rosa ^a   de Yebenes, Justo Garcia ^a   Mena, Maria Angeles ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROPROPIONIC ACID; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; CASPASE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMIC ACID; GLUTAMINE; GLUTATHIONE; HEAT SHOCK PROTEIN 70; HUNTINGTIN; NEUROTOXIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; REACTIVE OXYGEN METABOLITE; CHAPERONE; FREE RADICAL; LACTATE DEHYDROGENASE; NEUROTROPHIC FACTOR; FIBROBLAST GROWTH FACTOR; HYDROGEN PEROXIDE;

ARTICLE; CELL DEATH; CELL DIFFERENTIATION; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL SURVIVAL; GLIA; HUMAN; HUNTINGTON CHOREA; IN VITRO STUDY; NEURAL STEM CELL; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; UBIQUITINATION; ANIMAL CELL; ASTROCYTE; CONTROLLED STUDY; CYTOTOXICITY; DENSITOMETRY; ELECTROPHORESIS; FLUORESCENCE MICROSCOPY; GLIA CELL; IMMUNOCYTOCHEMISTRY; IMMUNODETECTION; MOUSE; WESTERN BLOTTING; APOPTOSIS; CULTURE MEDIUM;

EID: 84867459086     PISSN: None     EISSN: 21573999     Source Type: Journal    
DOI: 10.1371/4fbca54a2028b     Document Type: Article

References (56)

1. Bamford KA, Caine ED, Kido DK et al. (1989) Clinical-pathologic correlation in Huntington's disease: a neuropsychological and computed tomography study. Neurology 39:796-801
2. Caine ED, Hunt RD, Weingartner H, Ebert MH (1978) Huntington's dementia. Clinical and neuropsychological features. Arch Gen Psychiatry 35:377-384
3. Vonsattel JP, Keller C, Cortes Ramirez EP (2011) Huntington's disease - neuropathology. Handb Clin Neurol 100:83-100
4. Li SH, Li XJ (2004) Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet 20:146-154
5. Zuccato C, Valenza M, Cattaneo E (2010) Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 90:905-981
6. Rubio I, Rodriguez-Navarro JA, Tomas-Zapico C et al. (2009) Effects of partial suppression of parkin on huntingtin mutant R6/1 mice. Brain Res 1281:91-100
7. Han I, You Y, Kordower JH et al. (2010) Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features. J Neurochem113:1073-1091
8. Ribeiro FM, Paquet M, Ferreira LT et al. (2010) Metabotropic glutamate receptor-mediated cell signaling pathways are altered in a mouse model of Huntington's disease. J Neurosci 30:316-324
9. Ribeiro FM, Pires RG, Ferguson SS (2011) Huntington's disease and Group I metabotropic glutamate receptors. Mol Neurobiol 43:1-11
10. Duran R, Barrero FJ, Morales B et al. (2010) Oxidative stress and plasma aminopeptidase activity in Huntington's disease. J Neural Transm 117:325-332
11. Lander HM (1997) An essential role for free radicals and derived species in signal transduction. Faseb J 11:118-124
12. Solano RM, Casarejos MJ, Menendez-Cuervo J et al. (2008) Glial dysfunction in parkin null mice: effects of aging. J Neurosci 28:598-611
13. Marangolo M, McGee MM, Tipton KF et al. (2001) Oxidative stress induces apoptosis in C6 glioma cells: involvement of mitogen-activated protein kinases and nuclear factor kappa B. Neurotox Res 3:397-409
14. Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443:787-795
15. Oliveira JM (2010) Nature and cause of mitochondrial dysfunction in Huntington's disease: focusing on huntingtin and the striatum. J Neurochem 114:1-12
16. Politis M, Pavese N, Tai YF et al. (2011) Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. Hum Brain Mapp 32:258-270
17. Mena MA, Garcia de Yebenes J (2008) Glial cells as players in parkinsonism: the good, the bad, and the mysterious glia. Neuroscientist 14:544-560
18. Cicchetti F, Soulet D, Freeman TB (2011) Neuronal degeneration in striatal transplants and Huntington's disease: potential mechanisms and clinical implications. Brain 134:641-652
19. Bradford J, Shin JY, Roberts M et al. (2009) Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc Natl Acad Sci U S A 106:22480-22485
20. Besson MT, Dupont P, Fridell YW, Lievens JC (2010) Increased energy metabolism rescues glia-induced pathology in a Drosophila model of Huntington's disease. Hum Mol Genet 19:3372-3382
21. McGeer PL, McGeer EG (2008) Glial reactions in Parkinson's disease. Mov Disord 23:474-483
22. Mena MA, Casarejos MJ, Carazo A et al. (1997) Glia protect fetal midbrain dopamine neurons in culture from L-DOPA toxicity through multiple mechanisms. J Neural Transm 104:317-328
23. de Bernardo S, Canals S, Casarejos MJ et al. (2003) Glia-conditioned medium induces de novo synthesis of tyrosine hydroxylase and increases dopamine cell survival by differential signaling pathways. J Neurosci Res 73:818-830
24. Mena MA, Casarejos MJ, Estrada C, de Yebenes JG (1994) Effects of retinoic acid on NB 69 human neuroblastoma cells and fetal rat mid brain neurons. J Neural Transm Park Dis Dement Sect 8:85-97
25. Trettel F, Rigamonti D, Hilditch-Maguire P et al. (2000) Dominant phenotypes produced by the HD mutationin STHdh(Q111) striatal cells. Hum Mol Genet 9:2799-2809
26. Seong IS, Ivanova E, Lee JM et al. (2005) HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum Mol Genet 14:2871-2880
27. Gines S, Seong IS, Fossale E et al. (2003) Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice. Hum Mol Genet 12:497-508
28. Ruan Q, Lesort M, MacDonald ME, Johnson GV (2004) Striatal cells from mutant huntingtin knock-in mice are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a non-apoptotic pathway. Hum Mol Genet 13:669-681
29. Mao Z, Choo YS, Lesort M (2006) Cystamine and cysteamine prevent 3-NP-induced mitochondrial depolarization of Huntington's disease knock-in striatal cells. Eur J Neurosci 23:1701-1710
30. Milakovic T, Johnson GV (2005) Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin. J Biol Chem 280:30773-30782
31. Mena MA, Pardo B, Paino CL, De Yebenes JG (1993) Levodopa toxicity in foetal rat midbrain neurones in culture: modulation by ascorbic acid. Neuroreport 4:438-440
32. Pardo B, Paino CL, Casarejos MJ, Mena MA (1997) Neuronal-enriched cultures from embryonic rat ventral mesencephalon for pharmacological studies of dopamine neurons. Brain Res Brain Res Protoc 1:127-132
33. Casarejos MJ, Solano RM, Menendez J et al. (2005) Differential effects of l-DOPA on monoamine metabolism, cell survival and glutathione production in midbrain neuronal-enriched cultures from parkin knockout and wildtype mice. J Neurochem 94:1005-1014
34. Tietze F (1969) Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem 27:502-522
35. Tong WM, Cortes U, Wang ZQ (2001) Poly(ADP-ribose) polymerase: a guardian angel protecting the genome and suppressing tumorigenesis. Biochim Biophys Acta 1552:27-37
36. Lin LF, Doherty DH, Lile JD et al. (1993) GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260:1130-1132
37. Hoffer BJ, Hoffman A, Bowenkamp K et al. (1994) Glial cell line-derived neurotrophic factor reverses toxininduced injury to midbrain dopaminergic neurons in vivo. Neurosci Lett 182:107-111
38. Takeshima T, Johnston JM, Commissiong JW (1994) Mesencephalic type 1 astrocytes rescue dopaminergic neurons from death induced by serum deprivation. J Neurosci 14:4769-4779
39. Muller HW, Junghans U, Kappler J (1995) Astroglial neurotrophic and neurite-promoting factors. Pharmacol Ther 65:1-18
40. Engele J, Schubert D, Bohn MC (1991) Conditioned media derived from glial cell lines promote survival and differentiation of dopaminergic neurons in vitro: role of mesencephalic glia. J Neurosci Res 30:359-371
41. Mena MA, de Bernardo S, Casarejos MJ et al. (2002) The role of astroglia on the survival of dopamine neurons. Mol Neurobiol 25:245-263
42. Panchision DM, Martin-DeLeon PA, Takeshima T et al. (1998) An immortalized, type-1 astrocyte of mesencephalic origin source of a dopaminergic neurotrophic factor. J Mol Neurosci 11:209-221
43. Reuss B, Unsicker K (2000) Survival and differentiation of dopaminergic mesencephalic neurons are promoted by dopamine-mediated induction of FGF-2 in striatal astroglial cells. Mol Cell Neurosci 16:781-792
44. Chen CM (2011) Mitochondrial dysfunction, metabolic deficits, and increased oxidative stress in Huntington's disease. Chang Gung Med J 34:135-152
45. Browne SE, Bowling AC, MacGarvey U et al. (1997) Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol 41:646-653
46. Polidori MC, Mecocci P, Browne SE et al. (1999) Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex. Neurosci Lett 272:53-56
47. Li N, Liu B, Dluzen DE, Jin Y (2007) Protective effects of ginsenoside Rg2 against glutamate-induced neurotoxicity in PC12 cells. J Ethnopharmacol 111:458-463
48. Ankarcrona M, Dypbukt JM, Bonfoco E et al. (1995) Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron 15:961-973
49. Choi DW (1987) Ionic dependence of glutamate neurotoxicity. J Neurosci 7:369-379
50. Myers RH, Vonsattel JP, Stevens TJ et al. (1988) Clinical and neuropathologic assessment of severity in Huntington's disease. Neurology 38:341-347
51. Gil JM, Rego AC (2008) Mechanisms of neurodegeneration in Huntington's disease. Eur J Neurosci 27:2803- 2820
52. Beal MF, Brouillet E, Jenkins BG et al. (1993) Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 13:4181-4192
53. Shin, J.Y., Fang, Z.H., Yu, Z.X., Wang, C.E., Li, S.H. and Li, X.J (2005) Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J Cell Biol. 171:1001-1012
54. Sapp, E., Kegel, K.B., Aronin, N., Hashikawa, T., Uchiyama, Y., Tohyama, K., Bhide, P.G., Vonsattel, J.P. and DiFiglia, M (2001) Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol. 60: 161-172
55. Chou, S.Y., Weng, J.Y., Lai, H.L., Liao, F., Sun, S.H., Tu, P.H., Dickson, D.W. and Chern, Y (2008) Expandedpolyglutamine huntingtin protein suppresses the secretion and production of a chemokine (CCL5/RANTES) by astrocytes. J Neurosci. 28:3277-90
56. Bradford, J., Shin, J.Y., Roberts, M., Wang, C.E., Sheng, G., Li, S. and Li, X.J (2010) Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice. J Biol Chem. 285:10653-61.